Abstract 42P
Background
IPARPs are the latest advance in ovarian cancer treatment and have been shown and have been shown in clinical trials to be an effective and safe treatment. The increase in life expectancy implies an increase in the age of the patients treated, so the development of effective drugs with few adverse effects is becoming more important every day. The objective of the study was to establish the clinical and toxicity differences of iPARP treatment between patients older and younger than 65 years.
Methods
A retrospective, single-center study was conducted. All patients diagnosed of high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer treated with iPARPs between 2017 and 2021 in Puerta de Hierro Hospital were included. Epidemiological and clinical data were registered.
Results
The table describes the characteristics of both populations. 60 patients were analyzed and 31.7% were >65 years. 25% received maintenance iPARP after a first platinum-based line. No differences in toxicity were observed between both groups. Within cardiological toxicity, tachycardias were significantly more frequent in the >65 years subgroup (7.3 vs 47.4% p= 0.0001). There was no difference in the suspension of treatment between both groups (9.8% vs 15.8% p= 0.231). No patient died as a result of an adverse event to the treatment Table: 42P
| Characteristics | <65 years (41) | >65 years (19) | |
| Comorbidities:HypertensionDiabetesHypercholesterolemiaIschemic eventHeart failure | 7.3%2.4%14.6%2.4%0% | 26.3%10.5%21.0%0%5.26% | |
| Smoking habitCurrentFormer | 14.6%29.3% | 1%36.8% | |
| Stage at diagnosis | I-II: 14.6%III-IV: 86.4% | I-II: 15.8III-IV: 84.4% | |
| Toxicity (any) | 43.9% | 63.2% | p=0.165 |
| Grade >G3 | 14.6% | 5.3% | P=0.293 |
| ToxicityGastrointestinalCardiologicalHematologicalOthers: | 33%22.2%33.4%5.5% | 50%25%21%4% | |
| Median treatment duration (months) | 11.5 | 7 | |
| Discontinuation: | 9.8% | 21.0% | P= 0.231 |
| Delays: | 9.8% | 15.8% | P=0.498 |
| Subsequent treatment | 68.2% | 71.4% | P=0.333 |
Conclusions
Patients >65 years treated with iPARPs did not experience higher rates of adverse events or treatment interruptions/discontinuations. iPARPs should be a valid treatment option for ovarian cancer in this increasingly frequent subgroup of patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.